ZA200105165B - Treatment and prevention of reactive oxygen metabolite-mediated cellular damage. - Google Patents
Treatment and prevention of reactive oxygen metabolite-mediated cellular damage.Info
- Publication number
- ZA200105165B ZA200105165B ZA200105165A ZA200105165A ZA200105165B ZA 200105165 B ZA200105165 B ZA 200105165B ZA 200105165 A ZA200105165 A ZA 200105165A ZA 200105165 A ZA200105165 A ZA 200105165A ZA 200105165 B ZA200105165 B ZA 200105165B
- Authority
- ZA
- South Africa
- Prior art keywords
- reactive oxygen
- prevention
- treatment
- roms
- cellular damage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/227,455 US6242473B1 (en) | 1999-01-08 | 1999-01-08 | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200105165B true ZA200105165B (en) | 2002-06-12 |
Family
ID=22853182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200105165A ZA200105165B (en) | 1999-01-08 | 2001-06-22 | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage. |
Country Status (16)
Country | Link |
---|---|
US (6) | US6242473B1 (xx) |
EP (2) | EP1410798A3 (xx) |
JP (1) | JP2002534384A (xx) |
KR (1) | KR20010101416A (xx) |
CN (1) | CN1203851C (xx) |
AT (1) | ATE275954T1 (xx) |
AU (1) | AU768526B2 (xx) |
CA (1) | CA2358851A1 (xx) |
DE (1) | DE60013764T2 (xx) |
ES (1) | ES2228453T3 (xx) |
HK (1) | HK1040923B (xx) |
IL (1) | IL143970A0 (xx) |
PT (1) | PT1140077E (xx) |
TW (1) | TWI248816B (xx) |
WO (1) | WO2000040241A2 (xx) |
ZA (1) | ZA200105165B (xx) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8586298A (en) * | 1997-07-25 | 1999-02-16 | University Of Massachusetts | Designed protein pores as components for biosensors |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
US6270781B1 (en) * | 1999-01-08 | 2001-08-07 | Maxim Pharmaceuticals, Inc. | Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
US7341717B2 (en) * | 2001-04-13 | 2008-03-11 | Gpc Biotech Ag | Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor |
WO2002084294A2 (en) * | 2001-04-13 | 2002-10-24 | Axxima Pharmaceuticals Ag | Gastrointestinal glutathione peroxidase in hepatitis c virus infections |
EP1383497B1 (en) * | 2001-05-02 | 2008-10-15 | Blanchette Rockefeller Neurosciences Institute | Carbonic anhydrase activators for enhancing learning and memory |
KR20040058192A (ko) * | 2001-10-19 | 2004-07-03 | 맥심 파마수티컬즈 인크. | 간 질환 치료용으로서의 히스타민 용도 |
KR20050043763A (ko) * | 2001-11-06 | 2005-05-11 | 맥심 파마수티컬즈 인크. | 감염 질환의 치료용 조성물 |
JP2006512279A (ja) * | 2002-03-29 | 2006-04-13 | マキシム ファーマシューティカルス,インコーポレイテッド | 眼内損傷を治療および予防するためのrom生成および放出阻害剤の使用 |
US20040106896A1 (en) * | 2002-11-29 | 2004-06-03 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
CN1649641A (zh) * | 2002-05-08 | 2005-08-03 | 加利福尼亚大学董事会 | 形成非切除性心脏传导阻滞的系统和方法 |
CA2483105C (en) | 2002-05-13 | 2011-05-10 | Arexis Ab | Autoimmune conditions and nadph oxidase defects |
EP1380290A1 (en) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
US20040057983A1 (en) | 2002-09-25 | 2004-03-25 | David Schmidt | Biomolecular wearable apparatus |
US7317950B2 (en) * | 2002-11-16 | 2008-01-08 | The Regents Of The University Of California | Cardiac stimulation system with delivery of conductive agent |
AU2003297294A1 (en) * | 2002-11-20 | 2004-06-15 | Board Of Regents, The University Of Texas System | Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens |
GB0308382D0 (en) * | 2003-04-10 | 2003-05-21 | Univ Cambridge Tech | Therapeutic methods and means |
US7290197B2 (en) * | 2003-06-03 | 2007-10-30 | Quantum Corporation | Correcting data using redundancy blocks |
US20050171192A1 (en) * | 2003-12-11 | 2005-08-04 | Gehlsen Kurt R. | Use of histamine to treat bone disease |
TW200538181A (en) | 2004-05-18 | 2005-12-01 | Brni Neurosciences Inst | Treatment of depressive disorders |
EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
WO2007008072A2 (en) | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | CROSS-ß STRUCTURE BINDING COMPOUNDS |
US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
AU2006267177A1 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Methods for determining the effect of a treatment on the cross-beta structure content of a protein; selection of treatments and uses thereof |
EP1940816A2 (en) * | 2005-09-30 | 2008-07-09 | OMP, Inc. | Stable ascorbic acid compositions |
JP2009084155A (ja) * | 2006-01-16 | 2009-04-23 | Kanazawa Univ | レビー小体病治療薬及びレビー小体病予防薬 |
US8999933B2 (en) * | 2006-01-18 | 2015-04-07 | Biolitec Pharma Marketing Ltd | Photodynamic cosmetic procedure and healing method |
US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
US20070269534A1 (en) * | 2006-02-02 | 2007-11-22 | Ramirez Jose E | Methods of treating skin to enhance therapeutic treatment thereof |
US20070178058A1 (en) * | 2006-02-02 | 2007-08-02 | Ramirez Jose E | Methods of using stable ascorbic acid compositions |
EP2007800A1 (en) * | 2006-03-17 | 2008-12-31 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
EP2058001A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
EP2058000A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Immunogenic compositions capable of activating T cells |
US8602961B2 (en) * | 2008-05-15 | 2013-12-10 | Lifewave Products Llc | Apparatus and method of stimulating elevation of glutathione levels in a subject |
TW201029676A (en) * | 2009-02-05 | 2010-08-16 | Yuk Kwan Liu | Formulation for the treatment of hypoxia and related disorders |
PL2418945T3 (pl) | 2009-04-15 | 2019-05-31 | Bmg Pharma S P A | Kompozycje soli mineralnej - kwasu sulfonowego i sposoby ich stosowania |
WO2014066672A1 (en) * | 2012-10-26 | 2014-05-01 | Beech Tree Labs, Inc. | Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin |
EP4340838A1 (en) * | 2021-05-19 | 2024-03-27 | Alberto Paz | Orally administered compositions for cancer treatment |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3636202A (en) * | 1968-02-12 | 1972-01-18 | Lewis A Klein | Treatment of rheumatoid arthritis and related diseases |
SU512764A1 (ru) * | 1972-02-24 | 1976-05-05 | Войсковая Часть 64688 | Средство дл профилактики атеросклероза "аэровит" |
US3898325A (en) * | 1973-09-19 | 1975-08-05 | American Lipids Corp | Method and preparations for relieving pain and producing analgesia |
US4704273A (en) * | 1982-05-17 | 1987-11-03 | Mcmichael John | Methods and materials for treatment of rheumatoid arthritis |
DE3239870A1 (de) * | 1982-10-27 | 1984-05-03 | Gert Dr.med. 8000 München Baumann | Arzneimittel zur behandlung von chronischem und akutem herzversagen |
US5268291A (en) | 1983-01-19 | 1993-12-07 | Genentech, Inc. | Human t-PA production using vectors coding for DHFR protein |
US4573996A (en) | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
IL74222A (en) * | 1984-02-06 | 1988-07-31 | Lilly Co Eli | 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them |
US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
JPH0717504B2 (ja) * | 1985-03-09 | 1995-03-01 | 美浜 久春 | 血栓症予防及び治療用組成物 |
US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US5122127A (en) | 1985-05-01 | 1992-06-16 | University Of Utah | Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues |
US4843096A (en) * | 1985-06-26 | 1989-06-27 | Stiefel Laboratories, Inc. | Treatment of acne |
SU1394134A1 (ru) * | 1986-02-27 | 1988-05-07 | Тернопольский государственный медицинский институт | Способ исследовани секреторной функции желудка |
DE3616923A1 (de) * | 1986-05-20 | 1987-11-26 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on |
JPS6396123A (ja) * | 1986-10-13 | 1988-04-27 | Kuraray Co Ltd | ビタミンa酸亜鉛塩を含有する抗炎症剤 |
US5166134A (en) * | 1986-12-24 | 1992-11-24 | John Lezdey | Treatment of allergic rhinitis |
US4886665A (en) * | 1987-03-11 | 1989-12-12 | Arcopharma Ltd. | Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
DE3720493A1 (de) * | 1987-06-20 | 1989-01-26 | Nattermann A & Cie | Arzneizubereitungen mit mikronisierten ebselen-kristallen |
US4839174A (en) | 1987-10-05 | 1989-06-13 | Pharmetrix Corporation | Novel transdermal nicotine patch |
US4943435A (en) | 1987-10-05 | 1990-07-24 | Pharmetrix Corporation | Prolonged activity nicotine patch |
US5284647A (en) | 1988-03-18 | 1994-02-08 | Schering Aktiengesellschaft | Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them |
US5094953A (en) | 1988-03-21 | 1992-03-10 | Genentech, Inc. | Human tissue plasminogen activator variants |
US5214156A (en) * | 1988-03-25 | 1993-05-25 | The Upjohn Company | Therapeutically useful tetralin derivatives |
US5674706A (en) * | 1988-05-06 | 1997-10-07 | Chiron Corporation | High level expression of proteins in yeast |
DE3821392A1 (de) * | 1988-06-24 | 1989-12-28 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen) |
DE3831888A1 (de) * | 1988-09-20 | 1990-03-29 | Troponwerke Gmbh & Co Kg | Arzneimittel zur behandlung von apoplexia cerebri |
US4908213A (en) | 1989-02-21 | 1990-03-13 | Schering Corporation | Transdermal delivery of nicotine |
CA1335106C (en) * | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
IT1230140B (it) * | 1989-05-03 | 1991-10-14 | Fidia Spa | Derivati della serina, loro processo di preparazione e impiego in terapia umana |
US5637479A (en) * | 1989-06-23 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Method of modulating DNA binding activity of recombinant α-1 antichymotrypsin and other serine protease inhibitors |
US5723316A (en) * | 1989-06-23 | 1998-03-03 | Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin analogues having chymase inhibiting activity |
US5674708A (en) * | 1989-06-23 | 1997-10-07 | Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin analogues having elastase inhibitory activity |
US5134154A (en) * | 1989-10-20 | 1992-07-28 | Merrell Dow Pharmaceuticals Inc. | Phenoxy-heterocyclic compounds |
JPH0725786A (ja) * | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
US5215965A (en) * | 1990-10-02 | 1993-06-01 | John Lezdey | Treatment of inflammation |
US5607951A (en) * | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
DE4039631A1 (de) * | 1990-12-12 | 1992-06-17 | Troponwerke Gmbh & Co Kg | Neuroprotektive kombination |
US5679337A (en) | 1991-06-14 | 1997-10-21 | Professional Pharmaceutical, Inc. | Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient |
DK0601053T3 (da) | 1991-08-26 | 2001-01-08 | Abbott Lab | Præparater og fremgangsmåder til den sublinguale eller bukkale indgivelse af terapeutiske midler |
JPH05163160A (ja) * | 1991-12-13 | 1993-06-29 | Snow Brand Milk Prod Co Ltd | 免疫低下に伴う感染症の予防及び治療用栄養剤 |
GB9200623D0 (en) * | 1992-01-13 | 1992-03-11 | Bayer Ag | Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives |
US5244916A (en) * | 1992-01-31 | 1993-09-14 | The Scripps Research Institute | Inhibition of respiratory burst using posttranslational modification inhibitors |
AU667519B2 (en) * | 1992-02-07 | 1996-03-28 | Albert M. Kligman | Methods of treating inflammatory dermatoses |
JPH05213763A (ja) * | 1992-02-10 | 1993-08-24 | Sanwa Kagaku Kenkyusho Co Ltd | 易吸収活性化カルシウム製剤 |
US5219888A (en) * | 1992-03-31 | 1993-06-15 | American Cyanamid Company | Use of retinoids for the treatment of coronary artery disease |
CA2075517C (en) | 1992-04-01 | 1997-03-11 | John Wick | Transdermal patch incorporating a polymer film incorporated with an active agent |
SE513429C2 (sv) | 1992-06-03 | 2000-09-11 | Syntello Inc | Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer |
ATE246000T1 (de) | 1992-06-03 | 2003-08-15 | Genentech Inc | Varianten des gewebeplasminogenaktivators mit verbesserter therapeutischer wirkung |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
IT1260155B (it) * | 1992-08-03 | 1996-03-28 | Fidia Spa | Uso terapeutico della fosforil-l-serina-n-acil-sfingosina |
US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
US5376633A (en) * | 1992-09-30 | 1994-12-27 | Lezdey; John | Method for deactivating viruses in blood component containers |
US5834509A (en) * | 1992-12-07 | 1998-11-10 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
FR2699821A1 (fr) * | 1992-12-24 | 1994-07-01 | Pichot Eric | Traitement homéopathique préventif des maladies cardio-vasculaires (athérome, athérothrombomatose, infarctus du myocarde). |
US5474527A (en) | 1993-03-29 | 1995-12-12 | Bettinger; David S. | Positive displacement transdermal system |
US5686436A (en) * | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
US5457129A (en) * | 1993-05-17 | 1995-10-10 | Research Development Foundation | Inhibition of nitric oxide production by retinoic acid |
JPH08511785A (ja) * | 1993-06-17 | 1996-12-10 | チバ−ガイギー アクチェンゲゼルシャフト | プロテインキナーゼc阻害剤として有用なインドロカルバゾール |
US5549906A (en) | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
US5726155A (en) | 1993-08-02 | 1998-03-10 | The Scripps Research Institute | Regulation of oxidative burst using LMWG-derived peptides and analogs |
JP3193205B2 (ja) * | 1993-08-09 | 2001-07-30 | 日本臓器製薬株式会社 | 好酸球増多抑制剤 |
DE4329776A1 (de) * | 1993-09-03 | 1995-03-09 | Sandoz Ag | Naphthoxazine, ihre Herstellung und Verwendung |
NZ264634A (en) * | 1993-10-11 | 1995-12-21 | Sanofi Sa | 1-heteroaryl-4-alkyl-4-amino-piperidines and pharmaceutical compositions thereof and piperidine precursors |
GB9325395D0 (en) * | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
GB2285047B (en) * | 1993-12-21 | 1998-04-15 | Yamanouchi U K Ltd | Polypeptides which inhibit the NADPH oxidase complex |
US5399562A (en) * | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
KR970702247A (ko) * | 1994-03-30 | 1997-05-13 | 고야 마사시 | 벤조산 화합물 및 이들의 약제로서의 용도(benzoic acid compound and use thereof as medicine) |
JPH07313180A (ja) * | 1994-05-19 | 1995-12-05 | Mercian Corp | 新規ポリエン化合物 |
AU2880595A (en) * | 1994-07-06 | 1996-01-25 | Bo Arne Hofmann | Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses |
JPH10504304A (ja) | 1994-08-08 | 1998-04-28 | マキシム ファーマシューティカルズ,インコーポレイテッド | ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強 |
GB9416921D0 (en) * | 1994-08-22 | 1994-10-12 | Conway Gitta C | A nutritional preparation |
US5502080A (en) * | 1994-11-01 | 1996-03-26 | Hitzig; Pietr | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders |
FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
AU4467396A (en) * | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
US5804203A (en) | 1994-12-21 | 1998-09-08 | Cosmederm Technologies | Topical product formulations containing strontium for reducing skin irritation |
US5489611A (en) * | 1995-02-10 | 1996-02-06 | Warner-Lambert Company | Method for lowering plasma levels of lipoprotein (a) |
US5830453A (en) * | 1995-05-19 | 1998-11-03 | Emory University | Use of IL-13 to induce 15-lipoxygenase |
US5637497A (en) * | 1995-06-28 | 1997-06-10 | Alcon Laboratories, Inc. | Apparatus and method for cleaning and disinfecting contact lenses |
FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
US5763496A (en) * | 1995-11-27 | 1998-06-09 | The Research Foundation Of State University Of New York | Prevention of atherosclerosis using NADPH oxidase inhibitors |
US5597585A (en) * | 1995-12-26 | 1997-01-28 | Williams; Andrew H. | Vitamin/mineral composition |
WO1997038692A1 (en) * | 1996-04-12 | 1997-10-23 | Eli Lilly And Company | Bisindoles for treating pain or nociception |
US5961969A (en) * | 1996-05-14 | 1999-10-05 | Maxim Pharmaceuticals, Inc. | Stable circulating histamine levels |
US6071942A (en) * | 1996-05-14 | 2000-06-06 | Maxim Pharmaceuticals, Inc. | Elevation of circulating blood histamine levels |
WO1997044062A1 (en) * | 1996-05-23 | 1997-11-27 | Alcon Laboratories, Inc. | The use of 5-ht1b/1d agonists to treat ocular pain |
TW336325B (en) * | 1996-05-24 | 1998-07-11 | Electrocopper Products Ltd | Copper wire and process for making copper wire |
US5780440A (en) * | 1996-06-17 | 1998-07-14 | Protease Sciences Inc. | Treatment of pulmonary disease with protease inhibitors |
US5939460A (en) | 1996-07-08 | 1999-08-17 | Idun Pharmaceuticals, Inc. | Method of inhibiting NADPH oxidase |
JPH10120700A (ja) * | 1996-10-17 | 1998-05-12 | Takeda Chem Ind Ltd | ヒスタミン産生増大因子およびその用途 |
WO1998031384A1 (en) * | 1997-01-22 | 1998-07-23 | The Wistar Institute Of Anatomy & Biology | Methods and compositions using interleukin-13 for enhancing immune responses |
CN1217698C (zh) * | 1998-08-24 | 2005-09-07 | 马克西姆药品公司 | 应用h2受体激动剂和其它t细胞活化剂激活和保护t细胞(cd4+和cd8+) |
US6270781B1 (en) * | 1999-01-08 | 2001-08-07 | Maxim Pharmaceuticals, Inc. | Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
-
1999
- 1999-01-08 US US09/227,455 patent/US6242473B1/en not_active Expired - Fee Related
- 1999-08-26 TW TW088114611A patent/TWI248816B/zh active
-
2000
- 2000-01-07 PT PT00902340T patent/PT1140077E/pt unknown
- 2000-01-07 CA CA002358851A patent/CA2358851A1/en not_active Abandoned
- 2000-01-07 CN CNB008045828A patent/CN1203851C/zh not_active Expired - Fee Related
- 2000-01-07 EP EP03026944A patent/EP1410798A3/en not_active Withdrawn
- 2000-01-07 ES ES00902340T patent/ES2228453T3/es not_active Expired - Lifetime
- 2000-01-07 EP EP00902340A patent/EP1140077B1/en not_active Expired - Lifetime
- 2000-01-07 JP JP2000591998A patent/JP2002534384A/ja active Pending
- 2000-01-07 KR KR1020017008621A patent/KR20010101416A/ko not_active Application Discontinuation
- 2000-01-07 AT AT00902340T patent/ATE275954T1/de not_active IP Right Cessation
- 2000-01-07 DE DE60013764T patent/DE60013764T2/de not_active Expired - Fee Related
- 2000-01-07 AU AU24075/00A patent/AU768526B2/en not_active Ceased
- 2000-01-07 WO PCT/US2000/000314 patent/WO2000040241A2/en not_active Application Discontinuation
- 2000-01-07 IL IL14397000A patent/IL143970A0/xx unknown
- 2000-11-06 US US09/707,343 patent/US6462067B1/en not_active Expired - Fee Related
-
2001
- 2001-04-12 US US09/833,896 patent/US6407133B2/en not_active Expired - Fee Related
- 2001-06-22 ZA ZA200105165A patent/ZA200105165B/xx unknown
-
2002
- 2002-04-10 HK HK02102711.2A patent/HK1040923B/zh not_active IP Right Cessation
- 2002-06-11 US US10/171,018 patent/US6730692B2/en not_active Expired - Lifetime
- 2002-09-19 US US10/251,420 patent/US20030017145A1/en not_active Abandoned
-
2004
- 2004-04-07 US US10/819,594 patent/US20040191239A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000040241A3 (en) | 2000-11-30 |
AU768526B2 (en) | 2003-12-18 |
US20010023256A1 (en) | 2001-09-20 |
AU2407500A (en) | 2000-07-24 |
CA2358851A1 (en) | 2000-07-13 |
PT1140077E (pt) | 2005-01-31 |
IL143970A0 (en) | 2002-04-21 |
US20040191239A1 (en) | 2004-09-30 |
CN1203851C (zh) | 2005-06-01 |
CN1342079A (zh) | 2002-03-27 |
US6462067B1 (en) | 2002-10-08 |
JP2002534384A (ja) | 2002-10-15 |
US6242473B1 (en) | 2001-06-05 |
US20030017145A1 (en) | 2003-01-23 |
ATE275954T1 (de) | 2004-10-15 |
WO2000040241A2 (en) | 2000-07-13 |
US6407133B2 (en) | 2002-06-18 |
HK1040923B (zh) | 2005-04-01 |
DE60013764T2 (de) | 2005-09-29 |
HK1040923A1 (en) | 2002-06-28 |
ES2228453T3 (es) | 2005-04-16 |
KR20010101416A (ko) | 2001-11-14 |
EP1410798A3 (en) | 2004-10-13 |
EP1410798A2 (en) | 2004-04-21 |
US6730692B2 (en) | 2004-05-04 |
TWI248816B (en) | 2006-02-11 |
DE60013764D1 (de) | 2004-10-21 |
US20020150565A1 (en) | 2002-10-17 |
EP1140077B1 (en) | 2004-09-15 |
EP1140077A2 (en) | 2001-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL143970A0 (en) | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage | |
MY133365A (en) | Extended release buccal bioadhesive tablet | |
EP1222302A4 (en) | METHOD FOR PRODUCING CHOLESTERINE-REDUCING COMPOSITIONS FROM HIGHER BASIDIOMYCETES, AND RELATED METHODS | |
AU2001239873A1 (en) | Adjuvant treatment by in vivo activation of dendritic cells | |
ES2168006T3 (es) | Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion. | |
DE69942732D1 (de) | Verfahren zur Herstellung von Metaboliten die via Phosphoribosyl-Pyrophospat biologisch synthetisiert werden | |
CA2422359A1 (en) | Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds | |
WO2002057415A3 (en) | Method for altering cell fate | |
HK1102081A1 (en) | In vitro production of transplantable cartilage tissue | |
AU3938102A (en) | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases | |
HK1047707A1 (zh) | (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途 | |
CA2121387A1 (en) | Method for Bleaching Lignocellulose-Containing Pulp | |
HUP0200738A2 (hu) | Eljárás az inkontinencia kezelésére | |
EP1244443A4 (en) | METHOD FOR INCREASING THE CONCENTRATION OF ASCORBIC ACID IN THE CEREBRAL TISSUES OF A SUBJECT | |
WO2001093865A3 (de) | Mittel zur therapie von demenzen | |
AU5827900A (en) | Method for plant water treatment for at least one partially closed water circuit | |
SG98385A1 (en) | Catalysts for methacrylic acid production and process for producing methacrylic acid | |
HUP0201424A3 (en) | Process for regenerating and recovering periodic acid and process for producing dialdehyde-carbohidrates | |
PL367401A1 (en) | Utilization of buprenorphine in urinary incontinence therapy | |
WO2001034553A3 (en) | 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use | |
GB0120581D0 (en) | S-nitrosothiols as agents for the treatment of circulatory dsyfunctions | |
EP1375505A4 (en) | OPTICALLY ACTIVE ALKENYLPHOSPHINIC ACID ESTERS AND METHOD FOR THE PRODUCTION THEREOF | |
EP1323821A4 (en) | METHOD FOR THE PRODUCTION OF NORMAL PARENCHYM CELLS, TISSUE OR ORGANS WITH A BIO INCUBATOR | |
GB9928193D0 (en) | Cell treatment method | |
AU2335100A (en) | Process for the treatment of white liquor |